Laquinimod treatment in the R6/2 mouse model. - Wikidata - wikimedia - TriplyDB

Laquinimod treatment in the R6/2 mouse model.

Laquinimod treatment in the R6/2 mouse model.

http://www.wikidata.org/entity/Q33890346

about

Removal of the Mitochondrial Fission Factor Mff Exacerbates Neuronal Loss and Neurological Phenotypes in a Huntington's Disease Mouse Model

P2860

Q57138614-20A74732-B824-4345-936D-B8F3B7056E45

P2860

Laquinimod treatment in the R6/2 mouse model.

http://www.wikidata.org/entity/Q33890346

description

2017 nî lūn-bûn

@nan

2017 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Laquinimod treatment in the R6/2 mouse model.

@ast

Laquinimod treatment in the R6/2 mouse model.

@en

type

label

Laquinimod treatment in the R6/2 mouse model.

@ast

Laquinimod treatment in the R6/2 mouse model.

@en

prefLabel

Laquinimod treatment in the R6/2 mouse model.

@ast

Laquinimod treatment in the R6/2 mouse model.

@en

P1433

Q33890346-1B6F5BA2-F3E0-47A1-B121-45E8955A1C84

P1476

Q33890346-772FE763-B543-4002-A3C7-E422FEAD2CF6

P2093

Q33890346-0417FF8C-0D99-4ABF-A90A-135091011852

Q33890346-4EE86BB8-B119-45F7-8868-6A4587F35C8A

Q33890346-578BF456-96B7-4B1B-B66E-EC90514EA980

Q33890346-BC085D75-AE75-47BE-A9E8-7A16C760685D

Q33890346-DEEF1075-DB8C-4CC9-AB54-76CE4A979F79

Q33890346-F11AEEFB-F144-4EA8-974F-598DE86E9CA6

Q33890346-F659E135-83DD-43F7-B281-6558801BC33F

P2860

Q33890346-02C6F0AD-6F48-40FC-AE63-609D76E2401A

Q33890346-07E92CEA-A670-4F5A-99E2-7F4827ABCFDD

Q33890346-08F24052-FB0C-4F7F-95C4-0CB0735BCCFB

Q33890346-0BD38DBD-7A5E-451F-B258-2BA6B3C6309A

Q33890346-0F0AF521-915C-40D2-8A9A-1769E2E702CB

Q33890346-1499346D-2866-4C9C-BCB7-CAB8A5D60ADE

Q33890346-14FEDAC4-6392-4BD5-BAEE-8370112E2BC2

Q33890346-17138828-378E-40F3-BB61-4F5431957A46

Q33890346-1B941242-0E2A-49AB-9BEB-C95868F16FEC

Q33890346-1C080BC6-E46E-42D8-99AB-11850844E7BA

P2888

Q33890346-03175AF4-8CB4-4624-B4E3-51EE02E7E4BD

P304

Q33890346-2954D643-E52E-4C56-BAEE-8C2B34CF6D4A

P31

Q33890346-7E568D1D-012B-4931-8D13-7D15741DF6F0

P356

Q33890346-D372A532-2F5A-41D9-B237-71C8BE90E8DF

P407

Q33890346-DC4573DD-FF58-4C28-B0DC-75A71D90CB5B

P433

Q33890346-27DC0155-21BB-4BF8-A81F-68610B512F22

P478

Q33890346-99D01FC8-1CE1-479E-A198-E667F8C5E2EB

P50

Q33890346-9A53C55A-D7B8-48D2-B2BB-2726525EC319

Q33890346-B90D2E34-F3A8-4FC8-8FEE-19B959913691

Q33890346-EBC5C6AC-CF75-440A-82E7-121B962B38BE

P577

Q33890346-A8022166-D273-4002-A45B-B13E5B10AEED

P6179

Q33890346-50396028-0945-4233-975C-46113F4130A5

P698

Q33890346-1EF6BF96-ACB6-4A8E-BFDD-FA4EBDA59310

P932

Q33890346-4443716D-36A7-4B56-8DE9-8E2833913858

P356

S41598-017-04990-1

P1433

Scientific Reports

P1476

Laquinimod treatment in the R6/2 mouse model.

@en

P2093

Alina Blusch

http://www.w3.org/2001/XMLSchema#string

Dominik Sehr

http://www.w3.org/2001/XMLSchema#string

Gisa Ellrichmann

http://www.w3.org/2001/XMLSchema#string

Janine Brunner

http://www.w3.org/2001/XMLSchema#string

Liat Hayardeny

http://www.w3.org/2001/XMLSchema#string

Oluwaseun Fatoba

http://www.w3.org/2001/XMLSchema#string

Ralf Gold

http://www.w3.org/2001/XMLSchema#string

P2860

Huntington's disease: underlying molecular mechanisms and emerging concepts

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.

Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease

Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

A cell-based screen for drugs to treat Huntington's disease.

Differential loss of striatal projection neurons in Huntington disease.

P2888

s41598-017-04990-1

P304

4947

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-04990-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Konstanze F Winklhofer

Michael R. Hayden

P577

2017-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090523184

http://www.w3.org/2001/XMLSchema#string

P698

28694434

http://www.w3.org/2001/XMLSchema#string

P932

5504033

http://www.w3.org/2001/XMLSchema#string